BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now
Advanced Search

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

19 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.EBI
Glaxosmithkline
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.EBI
Glaxosmithkline
Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.EBI
Janssen Research and Development
1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.EBI
Merck Research Laboratories
Lysine demethylases inhibitors.EBI
Kyoto Prefectural University of Medicine
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.EBI
University College London
Novel Compounds as PHD Inhibitors for Treating Heart, Lung, Liver, and Kidney Diseases.EBI
Smith, Gambrell & Russell
Discovery of N-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1-3 (HIF PHD1-3) for the Treatment of Anemia.EBI
Merck Research Laboratories
Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.EBI
Merck
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases.EBI
Cadila Healthcare
Isoindolin-1-on derivative, method for preparing same, and pharmaceutical composition comprising same as effective component for preventing or treating cancerBDB
Korea Research Institute of Chemical Technology
ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOFBDB
Bolt Biotherapeutics
Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapyBDB
Auckland Uniservices
Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease.BDB
Wichita State University
Pyrrolidine derivatives and their use as complement pathway modulatorsBDB
Novartis
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitorsBDB
Pfizer